AzTrials
AzTrials

NAFLDNAFLDNCT03587298

Use of Shear Wave Elastography to Assess Non-alcoholic Fatty Liver Disease (NAFLD)

An observational study of NAFLD, run by RWTH Aachen University at 1 site in Germany.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The aim of this study is to test a non-invasive imaging technique to reliably diagnose NAFLD in children and adolescents with obesity and assess the degree of fibrosis. Read more about this study

Who is it for?
Ages 6 to 18 yearsHealthy volunteers can take part
Conditions the study is for
NAFLD
What is being tested?
Real-Time (Supersonic)- 2D shear wave elastography (rt-SWE)
Type of treatment
Surgery or procedure
How many people
80 participants
Where
1 siteGermany
Study dates
15 Sep 2018to Aug 2021
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 18 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult

Study population: The patient group is recruited from the obesity consultation hour as well as the emergency consultation hour and the wards of the Clinic for Paediatrics and Youth Medicine at the University Hospital Aachen. The control group is recruited from the group of outpatients and inpatients receiving abdominal sonography from another indication and show no sonographic or laboratory chemical evidence of NAFLD. Patients in the control group are evaluated once.

Who may be able to join

  • male and male children and adolescents aged 6-18 years
  • obesity with a BMI above percentile 95 according to Kromeyer-Hauschild
  • NAFLD criteria met (by definition: sonographic fatty liver)
  • written informed consent
  • patients of matching age are included in the control group without any indication of NAFLD

Who cannot join

  • other chronic liver diseases
  • alcohol consumption (more than 20g for girls and 30g for boys per day), after explicit anamnesis
  • persons who are accommodated in an institution by court or official order

Trial locations and contacts

1 site in 1 country.

Angeliki Pappas, Dr. med. contact

0241 80-89206

apappa@ukaachen.de

Evangelia-Vera Papagrigoraki contact

epapagrigora@ukaachen.de

Germany1 site, 1 recruiting
  • Paediatric Clini; RWTH Aachen University Hospital

    Aachen, North Rhine-Westphalia, 52074

    Recruiting

Other trials in Germany

About this study

Official title: Use of Shear Wave Elastography in Adolescents and Children With Obesity to Assess Non-alcoholic Fatty Liver Disease (NAFLD)

The aim of this study is to test a non-invasive imaging technique to reliably diagnose NAFLD in children and adolescents with obesity and assess the degree of fibrosis.

Read the detailed description

NAFLD (non-alcoholic fatty liver disease) is by far the most common form of chronic liver disease worldwide. It is estimated that it affects up to 1/3 of the adult population in industrialized countries and additionally more and more children are affected. The term NAFLD covers a broad spectrum of diseases ranging from simple hepatic steatosis (accumulation of fat in hepatocytes) to NASH (non-alcoholic steatohepatitis). The latter is a progression of liver steatosis with inflammation, fibrosis and chronic inflammatory structural changes. Up to 20% of a NASH develops liver cirrhosis, more rarely also a hepatocellular carcinoma.

It is known that the degree of fibrosis is the most important parameter for the clinical course and prognosis. In addition, patients with mild lobular inflammation or fibrosis (regardless of severity) have an increased risk of developing NASH compared to patients with exclusive steatosis. A significant number of patients with NAFL may develop fibrotising NASH (5-20%). This is particularly the case when metabolic factors continue to deteriorate.

Liver biopsy remains the gold standard for the diagnosis of NAFLD. In particular, differentiation between NAFL and NASH and the degree of fibrosis are still only possible using histology. The invasive nature of the procedure involves risks to the patient's health such as bleeding, injuries to other organs or nerves, and complications of anesthesia. Furthermore, since the biopsy is taken selectively as a liver biopsy, it is possible to test a sample that does not adequately represent the degree of actual fibrosis, since regional differences in the severity of liver fibrosis can often be present. In addition, the liver biopsy is associated with considerable costs. Accordingly, liver biopsy is not an optimal diagnostic procedure and is hardly suitable as a diagnostic method for short-term follow-up under therapy. For this reason, a reliable, non-invasive method has long been sought to diagnose NAFLD, to distinguish NASH from steatosis, to assess the degree of fibrosis and which allows a less stressful assessment of the course of the liver.

Imaging procedures are available here. B-image sonography is already routinely used in children and adolescents with suspected or proven NASH for the detection of liver remodeling processes, in particular fibrosis. B-scan sonography is an excellent method for determining the presence and extent of hepatic steatosis, but the detection and graduation of liver fibrosis using B-mode sonography is only possible in very advanced stages.

In recent years, the determination of tissue stiffness in various organ systems and their pathologies, such as the breast, tendons and liver, has been successfully used in adults. Individual reports in adults give first indications that liver remodelling processes, in particular fibrosis by means of shear wave elastography (SWE), can be diagnosed in early stages. However, the evidence of the use of SWE in children to assess liver parenchyma changes, especially in NAFLD, is still insufficient. Therefore, in this study it will be investigated whether the rt-SWE provides reproducible values for liver stiffness and fibrosis in children and adolescents and by that a reliably diagnosis of NAFLD and assessment of the degree of fibrosis is possible.

The planned clinical examination and blood collection for laboratory chemical examinations are part of the routine follow-up of patients with obesity and steatosis hepatis. There will be no additional examinations, so there will be no greater burden on the young patients and no additional time expenditure.

Conditions
NAFLD
Being tested
Real-Time (Supersonic)- 2D shear wave elastography (rt-SWE)
Keywords
ShearWave Elastography
Medical subject headings
Non-alcoholic Fatty Liver Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Real-Time (Supersonic)- 2D shear wave elastography (rt-SWE)Procedure or surgery

    The SWE is carried out intercostally. If possible, the patient should hold the breath for 5-10 seconds. So-called colour charts are used, which indicate the derived liver stiffness in colour-coded form. In addition to the visual assessment of these colour charts, the quantitative ROI-based measurement of the SWE in kPa is performed in the "hardest" appearing areas. The measurement is performed at 5 different sites of the liver parenchyma and all SWE values are recorded.

Study groups in NCT03587298
Study groupRoleWhat they receive
Group 1NAFLK criteria met (by definition: sonographic fatty liver)
Receives: Procedure: Real-Time (Supersonic)- 2D shear wave elastography (rt-SWE)
Group 2Control group: matched age; no NAFKL
Receives: Procedure: Real-Time (Supersonic)- 2D shear wave elastography (rt-SWE)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Assess non-alcoholic fatty liver disease in adolescents and children with obesity by use of shear wave elastography

    stiffness (in kilopascals) of the liver measured with real-time shear wave elastography (RT-SWE) and hence regarding the amount of fibrosis in chronic liver disease

    Measured: 12 month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Jul 2018
  2. Study start15 Sep 2018
  3. Primary completionJul 2021 (estimated)
  4. Study completionAug 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
80 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03587298
Sponsor's protocol ID
18-056
Acronym
NAFLD
Status last verified
Mar 2021
First submitted
2 Jul 2018
Last updated
10 Mar 2021
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of NAFLD, run by RWTH Aachen University at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 10 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Angeliki Pappas, Dr. med. (0241 80-89206, apappa@ukaachen.de), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Assess non-alcoholic fatty liver disease in adolescents and children with obesity by use of shear wave elastography (time frame: 12 month). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Mar 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in